Literature DB >> 14513665

Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting.

June S Almenoff1, William DuMouchel, L Allen Kindman, Xionghu Yang, David Fram.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14513665     DOI： 10.1002/pds.885

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  31 in total

1.  Data mining in pharmacovigilance: the need for a balanced perspective.

Authors:  Manfred Hauben; Vaishali Patadia; Charles Gerrits; Louisa Walsh; Lester Reich
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Perspectives on the use of data mining in pharmaco-vigilance.

Authors:  June Almenoff; Joseph M Tonning; A Lawrence Gould; Ana Szarfman; Manfred Hauben; Rita Ouellet-Hellstrom; Robert Ball; Ken Hornbuckle; Louisa Walsh; Chuen Yee; Susan T Sacks; Nancy Yuen; Vaishali Patadia; Michael Blum; Mike Johnston; Charles Gerrits; Harry Seifert; Karol Lacroix
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems.

Authors:  Yifeng Qian; Xiaofei Ye; Wenmin Du; Jingtian Ren; Yalin Sun; Hainan Wang; Baozhang Luo; Qingbin Gao; Meijing Wu; Jia He
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

4.  Adverse event detection in drug development: recommendations and obligations beyond phase 3.

Authors:  Jesse A Berlin; Susan C Glasser; Susan S Ellenberg
Journal:  Am J Public Health       Date:  2008-06-12       Impact factor: 9.308

5.  Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.

Authors:  Johanna Strandell; Ola Caster; Andrew Bate; Niklas Norén; I Ralph Edwards
Journal:  Drug Saf       Date:  2011-03-01       Impact factor: 5.606

6.  Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System.

Authors:  Rave Harpaz; Krystl Haerian; Herbert S Chase; Carol Friedman
Journal:  AMIA Annu Symp Proc       Date:  2010-11-13

Review 7.  Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death.

Authors:  Raymond L Woosley; Klaus Romero; Craig W Heise; Tyler Gallo; Jared Tate; Raymond David Woosley; Sophie Ward
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

Review 8.  Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?

Authors:  Preciosa M Coloma; Gianluca Trifirò; Vaishali Patadia; Miriam Sturkenboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

9.  Identifying unpredicted drug benefit through query of patient experiential knowledge: a proof of concept web-based system.

Authors:  Jill Pulley; Nik Nik Hassan; Gordon R Bernard; Jim N Jirjis; Jonathan Schildcrout; David Robertson; Daniel R Masys; Paul Harris
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

10.  Revisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilance.

Authors:  Manfred Hauben; Eric Y Hung
Journal:  Ther Adv Drug Saf       Date:  2016-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.